MedPath

Comparison of two drugs for quality of block in spinal anaesthesia

Completed
Conditions
Medical and Surgical,
Registration Number
CTRI/2022/08/044717
Lead Sponsor
IVY hospital mohali
Brief Summary

Comparison between dexmedetomidine and fentanyl, used as additive to 0.5% hyperbaric bupivacaine in spinal anaesthesia, for quality and duration of sensory-motor block and for duration of postoperative analgesia in patients undergoing total knee arthroplasty. Control group is the one in which normal saline is used as additive to 0.5% hyperbaric bupivacaine in spinal anaesthesia.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
90
Inclusion Criteria

ASA grade I and II posted for total knee arthroplasty under spinal anaesthesia.

Exclusion Criteria
  • ASA grade III and IV with severe systemic illness 2.
  • Pregnancy 3.
  • Patient with history of heart conduction abnormalities 4.
  • Patient on alpha blockers 5.
  • Any known hypersensitivity to the study drugs 6.
  • Any contraindications to SA such as local infection, coagulopathy.
  • Patient with neurologic disorders.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
duration and quality of sensory-motor block in spinal anaesthesia and duration of postoperative analgesiaduration of motor anaesthesia (time taken to reach Bromage 0 from Bromage III after administration of subarachnoid block) and time of first rescue analgesia (the first time patient complains of pain at surgical site after administration of subarachnoid block)
Secondary Outcome Measures
NameTimeMethod
Effect on hemodynamics plusany intraoperative and/or postoperative complications

Trial Locations

Locations (1)

IVY hospital, mohali

🇮🇳

Rupnagar, PUNJAB, India

IVY hospital, mohali
🇮🇳Rupnagar, PUNJAB, India
Dr Shalini S
Principal investigator
7340941441
dr.shalu83@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.